This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: November 14, 2005
Last updated: March 16, 2009
Last verified: March 2009
The purpose of this study is to determine whether Symbicort dosed according to the Symbicort Maintenance and Reliever Therapy (SMART) concept is superior to standard asthma treatment according to the local German treatment guidelines.

Condition Intervention Phase
Asthma Drug: Symbicort, used twice daily (b.i.d) and as needed (prn) Drug: Budesonide Turbuhaler 200 µg Drug: Fluticasone Discus 250 µg Drug: Formoterol Turbuhaler 4.5 µg Drug: Terbutaline Turbuhaler 0.5 mg Drug: Salbutamol pressurized metered dose inhaler (pMDI) 100 µg Drug: Salmeterol Discus 50 µg Drug: Budesonide/Formoterol Turbuhaler 160/4.5 µg Drug: Fluticasone/Salmeterol Discus 250/50 µg Drug: Fluticasone/Salmeterol Discus 500/50 µg Drug: Theophylline 200 mg Drug: Theophylline 300 mg Drug: Singulair 10 mg Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre Study

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Time to first severe asthma exacerbation

Secondary Outcome Measures:
  • Number of severe asthma exacerbations
  • Mean use of as-needed medication
  • Change in forced expiratory volume in 1 second (FEV1) from the end of run-in to the end of the study period
  • Prescribed asthma medication during the treatment period
  • Asthma Control Questionnaire (ACQ)
  • Patient's satisfaction with the treatment question
  • Health care contacts
  • Asthma medication
  • Time lost from paid and unpaid work
  • Serious adverse events (SAEs)
  • Discontinuations due to adverse events (AEs)

Estimated Enrollment: 1600
Study Start Date: December 2004
Study Completion Date: May 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with asthma, either well-controlled on a regular therapy with a combination of long-acting beta-agonists and inhaled corticosteroids or symptomatic on therapy with inhaled corticosteroids alone.

Exclusion Criteria:

  • Any other significant lung disease other than asthma
  • Any disease that might put patients at risk if they participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00252863

  Show 167 Study Locations
Sponsors and Collaborators
Principal Investigator: Heinrich Worth, MD Klinikum Fürth
  More Information Identifier: NCT00252863     History of Changes
Other Study ID Numbers: D5890L00011
Study First Received: November 14, 2005
Last Updated: March 16, 2009

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Formoterol Fumarate
Salmeterol Xinafoate
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Budesonide, Formoterol Fumarate Drug Combination
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists processed this record on August 18, 2017